Microbion Corporation
Microbion is a clinical-stage pharmaceutical company dedicated to developing a novel class of anti-infective drugs to treat resistant and difficult-to-treat infections. Their lead candidate, pravibismane, is the first in a new class with broad-spectrum activity and a unique mechanism of halting microbial cellular metabolism, including eradication of biofilms. The company focuses on local delivery approaches to improve efficacy and safety, with multiple clinical programs and significant backing from government and foundation grants. Recently, they received up to $2.1 million in funding support from the U.S. Navy in partnership with CUBRC Inc. to advance topical pravibismane.
Industries
Nr. of Employees
small (1-50)
Patents
Bismuth-thiols as antiseptics for epithelial tissues, acute and chronic wounds, bacterial biofilms and other indications
US-11564903-B2
View Details
Bismuth-thiols as antiseptics for epithelial tissues, acute and chronic wounds, bacterial biofilms and other indications
US-11564903-B2
View DetailsProducts
Development-stage antimicrobial candidate (metal-thiol class) — topical and inhaled formulations
A development-stage antimicrobial compound from a metal-thiol chemical family formulated as topical/local aqueous suspension for wound and implant-site use and as an inhaled suspension for pulmonary delivery; demonstrated broad-spectrum in vitro activity including antibiofilm activity and progressed through preclinical studies and early clinical phases.
Development-stage antimicrobial candidate (metal-thiol class) — topical and inhaled formulations
A development-stage antimicrobial compound from a metal-thiol chemical family formulated as topical/local aqueous suspension for wound and implant-site use and as an inhaled suspension for pulmonary delivery; demonstrated broad-spectrum in vitro activity including antibiofilm activity and progressed through preclinical studies and early clinical phases.
Services
Collaborative arrangements with external manufacturers to develop and supply metal-based active pharmaceutical ingredients for clinical and potential commercial use.
Collaborative preclinical development funded through grants and public/private partnerships to advance inhalation and topical programs, including IND-enabling work and manufacture of clinical material.
Collaborative development programs executed under government sponsorship to advance topical and other formulations, leveraging external government research and testing resources.
Collaborative arrangements with external manufacturers to develop and supply metal-based active pharmaceutical ingredients for clinical and potential commercial use.
Collaborative preclinical development funded through grants and public/private partnerships to advance inhalation and topical programs, including IND-enabling work and manufacture of clinical material.
Collaborative development programs executed under government sponsorship to advance topical and other formulations, leveraging external government research and testing resources.
Expertise Areas
- Clinical trial management
- Antimicrobial drug discovery
- Formulation development for topical and inhaled delivery
- Biofilm research and anti-biofilm assays
Key Technologies
- Microbial bioenergetic inhibition (ATP disruption)
- Metal-thiol antimicrobial chemistries
- Topical aqueous suspension formulations
- Inhalation/aerosol suspension formulations
News & Updates
The Phase 2 study demonstrated safety, tolerability, and promising efficacy signals, including wound closure and reduced amputations.
Studies showed pravibismane disrupts bacterial bioenergetics across various species, including planktonic and biofilm forms.
The FDA granted Fast Track status to MBN-101 for adjunctive treatment of diabetic foot ulcers, supporting accelerated development.
The company received up to $7.4 million to support IND-enabling studies and clinical development for CF-related lung infections.
Funding aims to advance topical pravibismane for potential military and civilian medical applications.
The WHO recommended pravibismane as the INN for the company's broad-spectrum antimicrobial agent, highlighting its potential to address unmet medical needs.
The Phase 2 study demonstrated safety, tolerability, and promising efficacy signals, including wound closure and reduced amputations.
Studies showed pravibismane disrupts bacterial bioenergetics across various species, including planktonic and biofilm forms.
The FDA granted Fast Track status to MBN-101 for adjunctive treatment of diabetic foot ulcers, supporting accelerated development.
The company received up to $7.4 million to support IND-enabling studies and clinical development for CF-related lung infections.
Funding aims to advance topical pravibismane for potential military and civilian medical applications.
The WHO recommended pravibismane as the INN for the company's broad-spectrum antimicrobial agent, highlighting its potential to address unmet medical needs.